Next Generation Precision Medicine Program

There is an urgent need for new and more precisely targeted medicines to treat childhood cancers. Currently, genomic sequencing is used to identify discrete mutations that could predict a child’s responses to targeted therapies. However, fewer than one in five children with cancer are found to have actionable mutations. And of those children, only half respond to the therapies that are available.

New treatment options are needed, particularly for paediatric cancers that have the poorest survival rates such as brain and soft tissue tumours.

The Next Generation Precision Medicine Program is led by Hudson Institute’s Professor Ron Firestein, a clinician-scientist and the Head of the Centre for Cancer Research at Hudson Institute. The Program is focused on

Generating novel models of childhood cancers that faithfully represent a patient’s tumour
Characterising those models at a multi-omics level (genome, transcriptome, epigenome, proteome) to find what makes them unique
Using comprehensive functional genomic screens that can identify the genetic drivers and dependencies of low-survival paediatric cancers
Developing a childhood cell line atlas and data portal to enable cohort-level integrative genomic analyses.

Childhood Cancer Model Atlas (CCMA)

The Childhood Cancer Model Atlas (CCMA) was created through this program. As the largest collection of high-risk paediatric solid tumour cell lines in the world, the CCMA is one of the most valuable resources available for childhood cancer researchers globally. It provides a collection of well annotated and characterised models of childhood cancer with associated functional genomics screens and includes a searchable data portal that can be accessed by scientists worldwide. This open-source approach, couple with precise, detailed data, helps scientists anywhere collaborate and drive clinical translation to help sick children.